247 related articles for article (PubMed ID: 22149999)
1. TroVax(®) vaccine therapy for renal cell carcinoma.
Zhang RT; Bines SD; Ruby C; Kaufman HL
Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
[TBL] [Abstract][Full Text] [Related]
2. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
3. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy for renal cancer.
Amato RJ
Expert Rev Vaccines; 2008 Sep; 7(7):925-35. PubMed ID: 18767943
[TBL] [Abstract][Full Text] [Related]
5. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.
Aalamian M; Fuchs E; Gupta R; Levey DL
Urol Oncol; 2006; 24(5):425-33. PubMed ID: 16962495
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
[TBL] [Abstract][Full Text] [Related]
8. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
Harrop R; Treasure P; de Belin J; Kelleher M; Bolton G; Naylor S; Shingler WH
Cancer Immunol Immunother; 2012 Dec; 61(12):2283-94. PubMed ID: 22692758
[TBL] [Abstract][Full Text] [Related]
9. Vaccines in renal cell carcinoma.
Kübler H; Vieweg J
Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for colorectal cancer and renal cell carcinoma.
Kabaker K; Shell K; Kaufman HL
Cancer J; 2011; 17(5):283-93. PubMed ID: 21952277
[TBL] [Abstract][Full Text] [Related]
12. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
13. TroVax in colorectal cancer.
Rowe J; Cen P
Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
[TBL] [Abstract][Full Text] [Related]
14. Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy.
Yoshimura K; Uemura H
Int J Urol; 2013 Aug; 20(8):744-55. PubMed ID: 23521119
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for melanoma and renal cell carcinoma.
Kaufman HL
Semin Oncol; 2012 Jun; 39(3):263-75. PubMed ID: 22595049
[TBL] [Abstract][Full Text] [Related]
18. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
19. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
Berntsen A; Geertsen PF; Svane IM
Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]